Anthrax Vaccine Market Size, Share & Forecast Analysis - 2032

Anthrax Vaccine Market – By Type (Cell Free PA Vaccine [Absorbed, Precipitated], Live Attenuated Vaccine), Application (Human Use, Veterinary Use), End-use (Veterinary Hospitals & Clinics, Hospital & Clinics) & Forecast (2024 – 2032)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Growing burden of anthrax globally

3.2.1.2&nbsp;&nbsp;&nbsp; Technology advancements in the vaccine development

3.2.1.3&nbsp;&nbsp;&nbsp; Increased globalization and travel

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Lack of awareness for diagnostic test of target disease

3.2.2.2&nbsp;&nbsp;&nbsp; High cost of vaccine

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5&nbsp;&nbsp;&nbsp; Pipeline analysis

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Type, 2021 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Cell free PA vaccine

5.2.1&nbsp;&nbsp;&nbsp; Anthrax vaccine absorbed (AVA)

5.2.2&nbsp;&nbsp;&nbsp; Anthrax vaccine precipitated (AVP)

5.3&nbsp;&nbsp;&nbsp; Live attenuated vaccine

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Veterinary use

6.3&nbsp;&nbsp;&nbsp; Human use

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End-use, 2021 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Veterinary hospitals &amp; clinics

7.3&nbsp;&nbsp;&nbsp; Hospital &amp; clinics

7.4&nbsp;&nbsp;&nbsp; Other end-users

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Netherlands

8.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; South Korea

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East and Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Altimmune Inc.

9.2&nbsp;&nbsp;&nbsp; Agrovet

9.3&nbsp;&nbsp;&nbsp; Bayer AG

9.4&nbsp;&nbsp;&nbsp; Bavarian Nordic

9.5&nbsp;&nbsp;&nbsp; Biogenesis Bago SA

9.6&nbsp;&nbsp;&nbsp; Ceva Sante Animale

9.7&nbsp;&nbsp;&nbsp; Colondo Serum Company

9.8&nbsp;&nbsp;&nbsp; Emergent BioSolutions

9.9&nbsp;&nbsp;&nbsp; Elusys Therapeutics Inc.

9.10&nbsp;&nbsp;&nbsp; Indian Immunologicals Ltd.

9.11&nbsp;&nbsp;&nbsp; Intervac (PVT) Ltd

9.12&nbsp;&nbsp;&nbsp; JOVAC

9.13&nbsp;&nbsp;&nbsp; Merck Co, Inc.

9.14&nbsp;&nbsp;&nbsp; Proton Biopharma Ltd. 
&nbsp;

Anthrax Vaccine Market

Get a free sample of this report